Katsunori Yanagihara
Overview
Explore the profile of Katsunori Yanagihara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
509
Citations
3678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwanaga N, Hosogaya N, Takazono T, Tsukamoto Y, Morio R, Irifune S, et al.
Cureus
. 2025 Mar;
17(3):e80404.
PMID: 40078884
Background And Objective: For treating community-acquired pneumonia (CAP) in adults, early switching from injectable to oral antimicrobials (switch therapy) is accepted once the clinical course is favorable. Lascufloxacin (LSFX) is...
2.
Kawasaki K, Sawai T, Inadomi Y, Morimitsu S, Ikeda T, Yoshioka S, et al.
J Infect Chemother
. 2025 Mar;
31(4):102662.
PMID: 40057275
Cyberlindnera fabianii, an ascomycetous yeast, is a rare human pathogen. Here, we describe the first reported case of central venous (CV) access port-related blood-stream infection caused by C. fabianii. An...
3.
Namie H, Takazono T, Kawasaki R, Yano H, Ito Y, Nakada N, et al.
Respir Investig
. 2025 Mar;
63(3):303-310.
PMID: 40048846
Background: Post-COVID-19 syndrome, referred to as "long COVID," is characterized by persistent symptoms that develop during or after SRAS-CoV-2 infection lasting for ≥12 weeks, which cannot be explained by factors...
4.
Takazono T, Hosogaya N, Ideguchi R, Yoshida M, Takeda K, Ide S, et al.
Cureus
. 2025 Mar;
17(3):e79891.
PMID: 40034415
Introduction complex pulmonary disease (MAC-PD) necessitates prolonged treatment. However, determining the appropriate time to conclude treatment is challenging because of the lack of indices for evaluating disease activity. Fluorodeoxyglucose positron...
5.
Murai Y, Murai Y, Nagaoka K, Nagaoka K, Iwanaga N, Iwanaga N, et al.
Int J Infect Dis
. 2025 Feb;
153:107840.
PMID: 39929321
Objectives: Routine clinical practice with extended anaerobic antibiotic coverage (EAC) has been recently reconsidered for several infections; however, its benefits remain unclear even in patients with anaerobic bacteremia (AB). Here,...
6.
Adewuyi O, Balogun M, Otomaru H, Abimiku A, Ahumibe A, Ilori E, et al.
Pathogens
. 2025 Jan;
14(1).
PMID: 39861062
Information on circulating HBV (sub-)genotype, variants, and hepatitis D virus (HDV) coinfection, which vary by geographical area, is crucial for the efficient control and management of HBV. We investigated the...
7.
Kosai K, Matsumoto K, Ishikawa T, Kawamoto Y, Akamatsu N, Ota K, et al.
Microorganisms
. 2025 Jan;
13(1.
PMID: 39858969
This study investigated the diagnostic efficiencies of two assays for the detection of complex: (1) the reciprocal-flow real-time polymerase chain reaction (PCR)-based GeneSoC assay and (2) the real-time PCR based...
8.
Kaku N, Ishige M, Yasutake G, Sasaki D, Ota K, Mitsumoto-Kaseida F, et al.
Emerg Microbes Infect
. 2025 Jan;
14(1):2449085.
PMID: 39789882
A 2019 nationwide study in Japan revealed the predominant methicillin-resistant Staphylococcus aureus (MRSA) types in bloodstream infections (BSIs) to be sequence type (ST)8-carrying SCC type IV (ST8-MRSA-IV) and clonal complex...
9.
Hirayama T, Miyazaki T, Tanaka R, Kitahori N, Yoshida M, Takeda K, et al.
Antimicrob Agents Chemother
. 2024 Dec;
69(2):e0150824.
PMID: 39692503
is an emerging pathogenic fungus that is highly resistant to existing antifungal drugs. Manogepix is a novel antifungal agent that exerts antifungal activity by inhibiting glycosylphosphatidylinositol anchor biosynthesis. Although the...
10.
Moriishi M, Takazono T, Hashizume J, Aibara N, Kutsuna Y, Okamoto M, et al.
Clin Biochem
. 2024 Dec;
135():110865.
PMID: 39689808
Background: The factors contributing to the development of severe coronavirus disease 2019 (COVID-19) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain unclear. Although the presence of immune...